Neuropeptides, Dopamine, and Schizophrenia

CHARLES B. NEMEROFF; GARTH BISSETTE

doi:10.1111/j.1749-6632.1988.tb42113.x

Neuropeptides, Dopamine, and Schizophrenia

CHARLES B. NEMEROFF, GARTH BISSETTE

Research output: Contribution to journal › Article › peer-review

34 Scopus citations

Abstract

In this paper, three types of evidence for the possible role of neuropeptides in the pathophysiology of schizophrenia are considered. First, studies in postmortem brain tissues and cerebrospinal fluid (CSF) have been conducted to determine whether the integrity or activity of neuropeptide-containing systems and their receptors is altered in schizophrenia. Second, studies in which peptides have been administered to schizophrenic patients to evaluate their potential therapeutic use are reviewed. Finally, the effects of peptide receptor antagonists on the symptoms of schizophrenic patients are reviewed.

Original language	English (US)
Pages (from-to)	273-291
Number of pages	19
Journal	Annals of the New York Academy of Sciences
Volume	537
Issue number	1
DOIs	https://doi.org/10.1111/j.1749-6632.1988.tb42113.x
State	Published - Oct 1988
Externally published	Yes

ASJC Scopus subject areas

Neuroscience(all)
Biochemistry, Genetics and Molecular Biology(all)
History and Philosophy of Science

Access to Document

10.1111/j.1749-6632.1988.tb42113.x

Fingerprint Dive into the research topics of 'Neuropeptides, Dopamine, and Schizophrenia'. Together they form a unique fingerprint.

Cite this

@article{9ba3e90614ce438b87b80da035e39966,

title = "Neuropeptides, Dopamine, and Schizophrenia",

abstract = "In this paper, three types of evidence for the possible role of neuropeptides in the pathophysiology of schizophrenia are considered. First, studies in postmortem brain tissues and cerebrospinal fluid (CSF) have been conducted to determine whether the integrity or activity of neuropeptide-containing systems and their receptors is altered in schizophrenia. Second, studies in which peptides have been administered to schizophrenic patients to evaluate their potential therapeutic use are reviewed. Finally, the effects of peptide receptor antagonists on the symptoms of schizophrenic patients are reviewed.",

author = "NEMEROFF, {CHARLES B.} and GARTH BISSETTE",

year = "1988",

month = oct,

doi = "10.1111/j.1749-6632.1988.tb42113.x",

language = "English (US)",

volume = "537",

pages = "273--291",

journal = "Annals of the New York Academy of Sciences",

issn = "0077-8923",

publisher = "Wiley-Blackwell",

number = "1",

}

TY - JOUR

T1 - Neuropeptides, Dopamine, and Schizophrenia

AU - NEMEROFF, CHARLES B.

AU - BISSETTE, GARTH

PY - 1988/10

Y1 - 1988/10

N2 - In this paper, three types of evidence for the possible role of neuropeptides in the pathophysiology of schizophrenia are considered. First, studies in postmortem brain tissues and cerebrospinal fluid (CSF) have been conducted to determine whether the integrity or activity of neuropeptide-containing systems and their receptors is altered in schizophrenia. Second, studies in which peptides have been administered to schizophrenic patients to evaluate their potential therapeutic use are reviewed. Finally, the effects of peptide receptor antagonists on the symptoms of schizophrenic patients are reviewed.

AB - In this paper, three types of evidence for the possible role of neuropeptides in the pathophysiology of schizophrenia are considered. First, studies in postmortem brain tissues and cerebrospinal fluid (CSF) have been conducted to determine whether the integrity or activity of neuropeptide-containing systems and their receptors is altered in schizophrenia. Second, studies in which peptides have been administered to schizophrenic patients to evaluate their potential therapeutic use are reviewed. Finally, the effects of peptide receptor antagonists on the symptoms of schizophrenic patients are reviewed.

UR - http://www.scopus.com/inward/record.url?scp=0024262541&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0024262541&partnerID=8YFLogxK

U2 - 10.1111/j.1749-6632.1988.tb42113.x

DO - 10.1111/j.1749-6632.1988.tb42113.x

M3 - Article

C2 - 3059929

AN - SCOPUS:0024262541

VL - 537

SP - 273

EP - 291

JO - Annals of the New York Academy of Sciences

JF - Annals of the New York Academy of Sciences

SN - 0077-8923

IS - 1

ER -

Neuropeptides, Dopamine, and Schizophrenia

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this